Published in Cancer Res on July 01, 1985
Radioimmunoscintigraphy of ocular melanoma with 99mTc labelled cutaneous melanoma antibody fragments. Br J Ophthalmol (1987) 1.06
Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer (1990) 0.97
Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res (2011) 0.90
A receptor for monomeric IgG2b on rat macrophages. Immunology (1987) 0.85
Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes. Br J Cancer (2000) 0.85
Design, synthesis, and preliminary in vitro and in vivo evaluation of N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide ([18F]-DAFBA): a novel potential PET probe to image melanoma tumors. Bioconjug Chem (2009) 0.83
Theranostic impact of NG2/CSPG4 proteoglycan in cancer. Theranostics (2015) 0.82
Radioimmunotherapy of malignancy using antibody targeted radionuclides. Br J Cancer (1986) 0.79
Anatomical and molecular imaging of skin cancer. Clin Cosmet Investig Dermatol (2008) 0.77
Imaging head and neck cancer using radioisotopes: a review. J R Soc Med (1988) 0.77
A comparative study of the relative sensitivity and specificity of radiolabelled monoclonal antibody and computerised tomography in the detection of sites of disease in human malignant melanoma. Br J Cancer (1989) 0.75
Kinetics, quantitative analysis and radioimmunolocalization using indium-111-HMFG1 monoclonal antibody in patients with breast cancer. Br J Cancer (1989) 0.75
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 4.46
Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med (1977) 3.45
Increased fetal loss in women with heritable thrombophilia. Lancet (1996) 3.34
Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer (1982) 2.71
Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2008) 2.67
Lack of effect of pregnancy on outcome of melanoma. For The World Health Organisation Melanoma Programme. Lancet (1991) 2.58
Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst (2001) 2.57
Stage I melanoma of the limbs: assessment of prognosis by levels of invasion and maximum thickness. Tumori (1978) 2.46
Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest (1996) 2.31
Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer (1995) 2.28
Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg (2000) 2.27
Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med (1988) 2.15
Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med (2000) 1.93
Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth (2010) 1.71
HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci U S A (1998) 1.67
Results of adjuvant interferon study in WHO melanoma programme. Lancet (1994) 1.62
ELISA for antibody measurement: aspects related to data expression. J Immunol Methods (1982) 1.59
Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer (1991) 1.58
Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer (1999) 1.54
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat (1999) 1.54
Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg (1991) 1.52
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52
Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost (1996) 1.51
The role of sentinel lymph node biopsy in patients with differentiated thyroid carcinoma. Eur J Surg Oncol (2006) 1.51
Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy (2001) 1.50
Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg (1983) 1.50
Prevention and treatment of central venous catheter sepsis by exchange via a guidewire. A prospective controlled trial. Ann Surg (1983) 1.48
Cell cycle-dependent initiation and lineage-dependent abrogation of GATA-1 expression in pure differentiating hematopoietic progenitors. Proc Natl Acad Sci U S A (1992) 1.45
Re.: Purification of IgG monoclonal antibody by caprylic acid precipitation. J Immunol Methods (1983) 1.45
The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg (2000) 1.43
Clinical diagnosis and therapy of cutaneous melanoma in situ. Cancer (1996) 1.43
Radiation dose to technicians per nuclear medicine procedure: comparison between technetium-99m, gallium-67, and iodine-131 radiotracers and fluorine-18 fluorodeoxyglucose. Eur J Nucl Med (1997) 1.42
Factor VII deficiency: defining the clinical picture and optimizing therapeutic options. Haemophilia (2008) 1.41
Factor VII clotting assay: influence of different thromboplastins and factor VII-deficient plasmas. CISMEL Study Group. Thromb Haemost (1991) 1.40
Stent thrombosis: incidence and related factors in the R.I.S.E. Registry(Registro Impianto Stent Endocoronarico) Catheter Cardiovasc Interv (1999) 1.40
Stereotactic excisional breast biopsy performed by interventional radiologists using the advanced breast biopsy instrumentation system. Br J Radiol (1998) 1.39
How alternative are immunoassay systems employing non-radioisotopic labels? A comparative appraisal of their main analytical characteristics. Q J Nucl Med (1995) 1.39
[The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors]. Radiol Med (1997) 1.39
One-year outcome in multivessel coronary disease patients undergoing coronary stenting. Catheter Cardiovasc Interv (1999) 1.38
Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol (2000) 1.35
Stage I melanoma of the skin: evaluation of prognosis according to histologic characteristics. Cancer (1981) 1.33
Pathogenesis and predictability of central venous catheter sepsis. Surgery (1982) 1.33
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol (2006) 1.29
Extensive use of peripheral angioplasty, particularly infrapopliteal, in the treatment of ischaemic diabetic foot ulcers: clinical results of a multicentric study of 221 consecutive diabetic subjects. J Intern Med (2002) 1.29
Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res (1997) 1.29
Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg (1985) 1.27
Campylobacter infections, Guillain-Barré syndrome, and parenteral gangliosides. Lancet (1991) 1.25
Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. J Natl Cancer Inst (1993) 1.23
Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol (1992) 1.20
Comparison of three different methods for radiolabelling human activated T lymphocytes. Eur J Nucl Med (1997) 1.18
Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations. Arterioscler Thromb Vasc Biol (1997) 1.17
Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol (2001) 1.17
Minimally invasive (99m)Tc-sestamibi radioguided surgery of parathyroid adenomas. Panminerva Med (2005) 1.16
Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol (2001) 1.15
Identification of a novel domain of HIV tat involved in monocyte chemotaxis. J Biol Chem (1998) 1.13
Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med (1998) 1.11
Promyelocytic leukemia-specific PML-retinoic acid alpha receptor fusion protein interferes with erythroid differentiation of human erythroleukemia K562 cells. Cancer Res (1995) 1.10
Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging (2011) 1.10
The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. Nucl Med Commun (2004) 1.09
Subunits A and S inheritance in four families with congenital factor XIII deficiency. Br J Haematol (1978) 1.08
A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer (1998) 1.08
Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. Cancer Res (1986) 1.08
(18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol (2005) 1.08
Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem (1999) 1.07
Multiple polymorphic sites in factor X locus. Blood (1988) 1.07
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med (1982) 1.06
Prognosis of malignant melanoma according to regional metastases. Am J Roentgenol Radium Ther Nucl Med (1971) 1.06
Subclavian venous thrombosis due to indwelling catheters: a prospective study on 52 patients. JPEN J Parenter Enteral Nutr (1984) 1.05
Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res (2000) 1.04
Uric acid metabolism in two patients with coexistent Down's syndrome and gout. Clin Rheumatol (1984) 1.04
Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res (1992) 1.04
Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med (2001) 1.03
Blood culture as a guide for the diagnosis of central venous catheter sepsis. JPEN J Parenter Enteral Nutr (1984) 1.02
In vitro human immunodeficiency virus-1 infection of purified hematopoietic progenitors in single-cell culture. Blood (1995) 1.02
Transforming growth factor-beta potentiates vitamin D3-induced terminal monocytic differentiation of human leukemic cell lines. J Immunol (1993) 1.02
Cellular and humoral immunity against human malignant melanoma. Int J Cancer (1971) 1.02
A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres. Q J Nucl Med Mol Imaging (2012) 1.01
ELISA for toxoplasma antibody detection: a comparison with other serodiagnostic tests. J Clin Pathol (1980) 1.01
Stage I melanoma of the limbs. Immediate versus delayed node dissection. Tumori (1980) 1.01
Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol (1986) 1.01
Evidence of cerebral hypoperfusion in scleroderma patients. Rheumatology (Oxford) (2000) 1.00
Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood (1985) 0.99
Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med (1998) 0.99
Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol (1984) 0.99
PLZF-mediated control on VLA-4 expression in normal and leukemic myeloid cells. Oncogene (2006) 0.99
Management of lymphatic fistulas by total parenteral nutrition. JPEN J Parenter Enteral Nutr (1983) 0.98
Control of erythroid cell production via caspase-mediated cleavage of transcription factor SCL/Tal-1. Cell Death Differ (2003) 0.98
Position of nuclear medicine modalities in the diagnostic work-up of breast cancer. Q J Nucl Med Mol Imaging (2004) 0.98
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol (2002) 0.97
Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res (1999) 0.97
A variant of von Willebrand's disease characterized by recessive inheritance and missing triplet structure of von Willebrand factor multimers. Blood (1983) 0.96
Productive HIV-1 infection of human vascular endothelial cells requires cell proliferation and is stimulated by combined treatment with interleukin-1 beta plus tumor necrosis factor-alpha. J Med Virol (1995) 0.96